Aligos Therapeutics, Inc. (ALGS) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ALGS Insider Trading Activity
ALGS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Activity of Aligos Therapeutics, Inc.
Over the last 12 months, insiders at Aligos Therapeutics, Inc. have bought $0 and sold $0 worth of Aligos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aligos Therapeutics, Inc. have bought $13.13M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,933,601 shares for transaction amount of $6M was made by Nuechterlein Carole () on 2023‑10‑25.
List of Insider Buy and Sell Transactions, Aligos Therapeutics, Inc.
| 2023-10-25 | Nuechterlein Carole | 7.93M 22.4566% | $0.76 | $6M | +4.10% | |||
| 2020-10-20 | Vivo Capital VIII, LLC | 10 percent owner | 550,000 1.9863% | $15.00 | $8.25M | +61.44% | ||
| 2020-10-20 | Novo Holdings A/S | 10 percent owner | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Woiwode Thomas | director | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Versant Venture Capital VI, L.P. | director | 400,000 1.4446% | $15.00 | $6M | +61.44% |
Insider Historical Profitability
| Nuechterlein Carole | 11025941 180.3156% | $64.39M | 1 | 0 | +4.1% | |
| Vivo Capital VIII, LLC | 10 percent owner | 3116658 50.9691% | $18.2M | 1 | 0 | +61.44% |
| Novo Holdings A/S | 10 percent owner | 2614563 42.7579% | $15.27M | 1 | 0 | +61.44% |
| Woiwode Thomas | director | 862444 14.1042% | $5.04M | 1 | 0 | +61.44% |
| Versant Venture Capital VI, L.P. | director | 862444 14.1042% | $5.04M | 1 | 0 | +61.44% |
Historical Insider Profitability vs. Competitors
$155,580,641 | 77 | -24.21% | $36.6M | |
$53,490,060 | 55 | 19.35% | $30.07M | |
$2,239,226 | 28 | 3.41% | $38.65M | |
$7,733,516 | 17 | 73.42% | $40.78M | |
$36,557,692 | 17 | 3.38% | $36.51M | |
$17,594,514 | 16 | -20.37% | $29.91M | |
$19,300,035 | 11 | 45.88% | $29.73M | |
$22,090,972 | 7 | -3.49% | $36.4M | |
$147,504 | 5 | -36.70% | $30.48M | |
$1,446,995 | 5 | -3.03% | $30.92M | |
Aligos Therapeutics, Inc. (ALGS) | $26,254,149 | 5 | 49.97% | $35.71M |
$149,996 | 5 | 16.26% | $39.44M | |
$657,791 | 4 | -52.05% | $34.88M | |
$5,045,759 | 4 | -11.33% | $27.94M | |
$25,999,992 | 4 | 13.36% | $29.74M | |
$67,369,250 | 3 | -22.09% | $36.06M | |
$157,740 | 3 | 153.95% | $38.33M | |
$100,266 | 2 | 3.17% | $31.29M | |
$150,000 | 1 | 5.48% | $35.81M |
ALGS Institutional Investors: Active Positions
| Increased Positions | 15 | +37.5% | 430,439 | +24.07% |
| Decreased Positions | 15 | -37.5% | 566,681 | -31.69% |
| New Positions | 8 | New | 256,840 | New |
| Sold Out Positions | 9 | Sold Out | 528,679 | Sold Out |
| Total Postitions | 40 | 0% | 2M | -7.62% |
ALGS Ownership Change vs Market
Institutional Investor Ownership
| Adage Capital Partners Gp, L.L.C. | $1,820.00 | 6.5% | 325,000 | +106,187 | +48.53% | 2024-12-31 |
| Ecor1 Capital, Llc | $1,431.00 | 5.11% | 255,573 | 0 | 0% | 2024-12-31 |
| Deep Track Capital, Lp | $1,367.00 | 4.88% | 244,110 | 0 | 0% | 2024-12-31 |
| Vivo Capital, Llc | $795.00 | 2.84% | 141,879 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $542.00 | 1.94% | 96,762 | +32,948 | +51.63% | 2024-12-31 |
| Baker Bros. Advisors Lp | $465.00 | 1.66% | 83,055 | 0 | 0% | 2024-12-31 |
| Hhlr Advisors, Ltd. | $427.00 | 1.53% | 76,247 | 0 | 0% | 2024-12-31 |
| Trexquant Investment Lp | $387.00 | 1.38% | 69,050 | +69,050 | New | 2024-12-31 |
| Ikarian Capital, Llc | $360.00 | 1.29% | 64,300 | +64,300 | New | 2024-12-31 |
| Oconnor, A Distinct Business Unit Of Ubs Asset Management Am | $225.00 | 0.8% | 40,096 | -27,000 | -40.24% | 2024-12-31 |